GlassScriptPhysician profile
Stacia Langan Sackmaster
NPI 1912330895
$2,846.08
in general payments reported to CMS, 2019-2025
19 companies · $1,912 in 2025
The $1,912 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.28 · 2022: $222 · 2023: $292 · 2024: $327 · 2025: $1,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,215 · Food and Beverage: $1,143 · Travel and Lodging: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,215.00 |
| Food and Beverage | $1,143.27 |
| Travel and Lodging | $173.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $1,808.92 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $349.13 | 2021-2025 | |
| Janssen Biotech, INC. | $167.65 | 2023-2025 | Tremfya, Stelara |
| Medtronic, INC. | $89.69 | 2023 | Interstim |
| Merck Sharp & Dohme LLC | $58.56 | 2021-2023 | Zinplava, Dificid |
| Janssen Scientific Affairs, LLC | $49.84 | 2022-2025 | Tremfya |
| Gilead Sciences, INC. | $45.73 | 2021-2025 | |
| Genzyme Corporation | $39.01 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.68 | 2022-2023 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $26.04 | 2022 | |
| Organon LLC | $25.34 | 2023 | Hadlima, Renflexis |
| Novo Nordisk INC | $23.71 | 2025 | Wegovy |
| Amgen INC. | $23.35 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.15 | 2021 | |
| Lilly USA, LLC | $18.31 | 2024 | Omvoh |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.70 | 2024 | |
| Phathom Pharmaceuticals, INC. | $15.90 | 2024 | Voquezna |
| Ardelyx, INC. | $15.49 | 2023 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacia Sackmaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.